首页> 外文期刊>Brain research. Developmental brain research >Expansion of mammalian neural stem cells in bioreactors: effect of power input and medium viscosity.
【24h】

Expansion of mammalian neural stem cells in bioreactors: effect of power input and medium viscosity.

机译:生物反应器中哺乳动物神经干细胞的扩增:功率输入和中等粘度的影响。

获取原文
获取原文并翻译 | 示例
       

摘要

Multipotent neural precursors can be cultured in suspension bioreactors as aggregates of stem cells and progenitor cells. However, it is important to limit the size of the aggregates, as necrotic centers may develop at very large diameters. Previously, we have shown that the hydrodynamics within a suspension bioreactor can be used to control the diameter of NSC aggregates (D(MAVG)<150 microm) below sizes where necrosis would be expected to occur. In the present study, power law correlations were developed for our bioreactors showing the dependence of the maximum mean aggregate diameter on both the kinematic viscosity of the medium and the power input per unit mass of medium. The power input was manipulated by changing the agitation rate (60-100 rpm), and the viscosity was manipulated through the addition of non-toxic levels of carboxymethylcellulose. The study also confirmed that the maximum liquid shear generated at the surface of the aggregates was sufficient to dislodge single cells, thus limiting the maximum diameter of the aggregates, without causing cell damage (tau(max)=9.76 dyn/cm(2)). This is a first step in the development of a reproducible, scaled-up process for the production of neural stem cells for therapeutic applications including the treatment of neurodegenerative disorders and acute central nervous system injuries.
机译:多能神经前体可以在悬浮生物反应器中作为干细胞和祖细胞的聚集体进行培养。然而,重要的是限制聚集体的大小,因为坏死中心可能会在很大的直径处发展。以前,我们已经表明,悬浮生物反应器内的流体动力学可用于控制NSC聚集体的直径(D(MAVG)<150微米),使其低于预期会发生坏死的大小。在本研究中,为我们的生物反应器开发了幂定律相关性,显示了最大平均聚集体直径对介质运动粘度和每单位质量介质的功率输入的依赖性。通过改变搅拌速度(60-100 rpm)来控制功率输入,并通过添加无毒水平的羧甲基纤维素来控制粘度。研究还证实,聚集体表面产生的最大液体剪切力足以去除单个细胞,从而限制了聚集体的最大直径,而不会引起细胞破坏(tau(max)= 9.76 dyn / cm(2))。 。这是开发可重复生产的放大工艺的第一步,该工艺可用于生产神经干细胞,用于治疗应用,包括治疗神经退行性疾病和急性中枢神经系统损伤。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号